Stem Cell Clinic

Insight on the Growth of Autologous Stem Cell Based Therapies Market Growth with Challenges, Standardization, Competitive Market Share and Top Players…

By adminJune 26, 2020Embryonic Stem Cells

The Autologous Stem Cell Based Therapies Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Autologous Stem Cell Based Therapies market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Autologous Stem Cell Based Therapies market reports provides all data with easily digestible information to guide every businessmans future innovation and move business forward.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2278181&source=atm

The worldwide Autologous Stem Cell Based Therapies market is an enlarging field for top market players,

The key players covered in this study Regeneus Mesoblast Pluristem Therapeutics Inc U.S. STEM CELL, INC. Brainstorm Cell Therapeutics Tigenix Med cell Europe

Market segment by Type, the product can be split into Embryonic Stem Cell Resident Cardiac Stem Cells Umbilical Cord Blood Stem Cells

Market segment by Application, split into Neurodegenerative Disorders Autoimmune Diseases Cardiovascular Diseases

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Autologous Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players. To present the Autologous Stem Cell Based Therapies development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Autologous Stem Cell Based Therapies are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2278181&source=atm

This Autologous Stem Cell Based Therapies report begins with a basic overview of the market. The analysis highlights the opportunity and Autologous Stem Cell Based Therapies industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Autologous Stem Cell Based Therapies insight regarding the things which are driving and affecting the earnings of the market. The Autologous Stem Cell Based Therapies report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2278181&licType=S&source=atm

Research objectives and Reason to procure this report:-

Finally, the global Autologous Stem Cell Based Therapies market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Autologous Stem Cell Based Therapies industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Go here to see the original:
Insight on the Growth of Autologous Stem Cell Based Therapies Market Growth with Challenges, Standardization, Competitive Market Share and Top Players...

How cancer cells resist radiotherapy – The Star Online

By adminJune 26, 2020Embryonic Stem Cells

Cancer stem cells are a cell type that was previously little known, but are now a controversial topic widely discussed in current cancer research.

A popular research subject, stem cells are precursor cells for various body cell types.

They play an important role in embryonic development, as well as in tissue maintenance.

Many types of cancer also involve a type of cell that shares many properties with stem cells.

While regular stem cells are precursors of healthy body cells, cancer stem cells are precursors of different types of cancer cells.

Normal stem cells and cancer stem cells therefore have many common aspects that are of interest to researchers.

One important factor is that cancer stem cells are resistant to irradiation and prevent the effective treatment of many types of cancer.

Cancer stem cells are a very contentious issue, explains molecular biologist Frdric Santer from the Department of Urology at the Medical University of Innsbruck, Austria.

It is still unclear whether they originate from normal stem cells or from differentiated, degenerate cells that are regressing.

Such processes are difficult to detect in living organisms.

However, he points out that the similarity of their properties is undisputed, in particular, their resistance to therapy.

The latter is a problem because cancer stem cells that survive therapy are held responsible for the recurrence of cancer in cured individuals.

The resistance of stem cells can be explained by natural necessities.

A certain resistance to environmental influences such as chemicals is useful for them, he says.

Regular cells have mechanisms that trigger cell death when DNA (deoxyribonucleic acid) is damaged.

Stem cells, on the other hand, are designed to regenerate damaged tissue.

So it makes sense that they survive in situations where other cells die, he explains.

How they manage to do that has not, however, been sufficiently researched.

But that is enormously important for cancer therapy, emphasises Santer, for whom this information deficit was inspiration for his research project, funded by the Austrian Science Fund (FWF).

We wanted to look at what happens at the level of genes during radiotherapy.

Two problems discovered

In order to do that, Santers team used tissue samples from patients with prostate cancer.

Unless it is very advanced, the primary therapy for prostate cancer is the surgical removal of the prostate.

This meant that the researchers had direct access to cancer cells from patients.

After surgery, the removed tissue is routinely sent to the pathology department, where a report is drawn up. Only then can Santers team use it for research.

It is not easy to cultivate these cells in the laboratory, he explains.

The process is complex and we had to invest a lot of time before we were able to create optimum conditions for the actual experiment.

After successful cultivation, the cell samples were irradiated in line with a protocol for radiotherapy that patients receive.

Irradiation causes DNA damage. If this damage is too extensive to be corrected by repair mechanisms, the cell normally dies, he explains.

However, some cells survived the irradiation process.

These cells were subsequently compared with the original tissue.

The researchers were particularly interested in gene expression, which refers to the process by which genes are translated into protein structures.

In the process, the genetic code in the cell nucleus is read and converted into RNA (ribonucleic acid).

An analysis of this RNA provides information about the processes taking place in a cell.

We found that two important processes of the radio-resistant cells are weakened, Santer shares.

One is the production of proteins that are regulated by interferons, which is used by the immune system to fight viruses and cancer cells.

In the irradiated cells, the production of proteins in the interferon cell-signalling pathway was inhibited.

This effect was also recently confirmed by another international study on breast cancer stem cells.

Another disrupted process was the cell cycle arrest, which involves a mechanism that prevents cell division in the presence of damaged DNA.

This mechanism was disrupted as certain proteins required for the process were not produced in sufficient quantities.

This actually constitutes a malfunction, but it helps the cell to survive because it can continue to reproduce without constraint despite the DNA damage, he says.

Both effects are problematic because they promote the development of cancer.

However, the more detailed understanding of these effects can now serve as a starting point for new cancer therapies, according to Santer. FWF

See more here:
How cancer cells resist radiotherapy - The Star Online

2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players – 3rd Watch News

By adminJune 26, 2020Stem Cell Medicine

The research reports on Exosome Technologies Market report gives detailed overview of factors that affect global business scope. Exosome Technologies Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Exosome Technologies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1781607

Top Companies in this Report-

Capricor Therapeutics Evox Therapeutics Ltd ReNeuron Group Plc Stem Cell Medicine Ltd Tavec Inc. Codiak Biosciences Inc. Therapeutic Solutions International Inc. ArunA Biomedical Inc. Ciloa

and more

Single User License: US $ 2995

Table of Contents

1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7

2 Exosomes in Healthcare 8 2.1 Overview of Exosomes 8 2.2 Drug Delivery Systems 9 2.2.1 Modified Release Drug Delivery Systems 9 2.2.2 Targeted Drug Delivery Systems 10 2.2.3 Liposomes 12 2.2.4 Viruses 14 2.2.5 Exosomes 17 2.3 The Exosome Lifecycle 18 2.4 Exosomes in Biology 18 2.5 Exosomes in Medicine 19 2.5.1 Biomarkers 19 2.5.2 Vaccines 20 2.6 Exosomes as a Therapeutic Target 20 2.7 Exosomes as Drug Delivery Vehicles 21 2.8 Therapeutic Preparation of Exosomes 21 2.8.1 Isolation and Purification 22 2.8.2 Drug Loading 22 2.8.3 Characterization 23 2.8.4 Bioengineering 23 2.8.5 Biodistribution and In Vivo Studies 23 2.8.6 Advantages of Exosome Therapies 24 2.8.7 Disadvantages of Exosome Therapies 24 2.9 Exosomes in Therapeutic Research 25 2.9.1 Exosome Gene Therapies 25 2.9.2 Exosome in Stem Cell Therapy 26 2.10 Exosomes in Oncology 27 2.10.1 Immunotherapy 27 2.10.2 Gene Therapy 28 2.10.3 Drug Delivery 29 2.10.4 Biomarkers 30 2.11 Exosomes in CNS Disease 30 2.11.1 Tackling the Blood-Brain Barrier 30 2.11.2 Exosomes in CNS Drug Delivery 31 2.11.3 Gene Therapy 32 2.12 Exosomes in Other Diseases 33 2.12.1 Cardiovascular Disease 33 2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36 3.1 Overview 36 3.2 Exosome Pipeline by Stage of Development and Molecule Type 36 3.3 Pipeline by Molecular Target 37 3.4 Pipeline by Therapy Area and Indication 38 3.5 Pipeline Product Profiles 38 3.5.1 AB-126 ArunA Biomedical Inc. 38 3.5.2 ALX-029 and ALX-102 Alxerion Biotech 39 3.5.3 Biologics for Autism Stem Cell Medicine Ltd 39 3.5.4 Biologic for Breast Cancer Exovita Biosciences Inc. 39 3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis Regenasome Pty 39 3.5.6 Biologic for Lysosomal Storage Disorder Exerkine 39 3.5.7 Biologics for Prostate Cancer Cells for Cells 40 3.5.8 CAP-2003 Capricor Therapeutics Inc. 40 3.5.9 CAP-1002 Capricor Therapeutics Inc. 41 3.5.10 CIL-15001 and CIL-15002 Ciloa 42 3.5.11 ExoPr0 ReNeuron Group Plc 42 3.5.12 MVAX-001 MolecuVax Inc. 43 3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke Isfahan University of Medical Sciences 44 3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer Codiak BioSciences Inc. 44 3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology Evox Therapeutics Ltd 44 3.5.16 TVC-201 and TVC-300 Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48 4.1 Interventional Clinical Trials 48 4.1.1 Clinical Trials by Therapy Type 48 4.1.2 Clinical Trials by Therapy Area 49 4.1.3 Clinical Trials by Stage of Development 50 4.1.4 Clinical Trials by Start Date and Status 50 4.2 Observational Clinical Trials 51 4.2.1 Clinical Trials by Therapy Type 51 4.2.2 Clinical Trials by Therapy Area 51 4.2.3 Clinical Trials by Stage of Development 52 4.2.4 Clinical Trials by Start Date and Status 53 4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67 5.1 Company Profiles 67 5.1.1 Capricor Therapeutics Inc. 67 5.1.2 Evox Therapeutics Ltd 72 5.1.3 ReNeuron Group Plc 73 5.1.4 Stem Cell Medicine Ltd 77 5.1.5 Tavec Inc. 78 5.1.6 Codiak Biosciences Inc. 80 5.1.7 Therapeutic Solutions International Inc. 81 5.1.8 ArunA Biomedical Inc. 83 5.1.9 Ciloa 85

Read the original here:
2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players - 3rd Watch News

Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 – Cole of Duty

By adminJune 26, 2020Stem Cell Clinics

LOS ANGELES, United States: QY Research has recently published a report, titled Global Canine Arthritis Therapeutics Market Size, Status and Forecast 2020-2026.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Canine Arthritis Therapeutics market. It informs readers about key trends and opportunities in the global Canine Arthritis Therapeutics market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Canine Arthritis Therapeutics market.

Key companies operating in the global Canine Arthritis Therapeutics market include , Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Canine Arthritis Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Canine Arthritis Therapeutics Market Segment By Type:

, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Stem Cell Therapy Canine Arthritis Therapeutics

Global Canine Arthritis Therapeutics Market Segment By Application:

, Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Canine Arthritis Therapeutics market.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Canine Arthritis Therapeutics Revenue 1.4 Market Analysis by Type 1.4.1 Global Canine Arthritis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Non-Steroidal Anti-Inflammatory Drugs 1.4.3 Opioids 1.4.4 Stem Cell Therapy 1.5 Market by Application 1.5.1 Global Canine Arthritis Therapeutics Market Share by Application: 2020 VS 2026 1.5.2 Veterinary Hospitals and Clinics 1.5.3 Retail Pharmacies 1.5.4 Drug Stores 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Canine Arthritis Therapeutics Market Perspective (2015-2026) 2.2 Canine Arthritis Therapeutics Growth Trends by Regions 2.2.1 Canine Arthritis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Canine Arthritis Therapeutics Historic Market Share by Regions (2015-2020) 2.2.3 Canine Arthritis Therapeutics Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Canine Arthritis Therapeutics Market Growth Strategy 2.3.6 Primary Interviews with Key Canine Arthritis Therapeutics Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Canine Arthritis Therapeutics Players by Market Size 3.1.1 Global Top Canine Arthritis Therapeutics Players by Revenue (2015-2020) 3.1.2 Global Canine Arthritis Therapeutics Revenue Market Share by Players (2015-2020) 3.1.3 Global Canine Arthritis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Canine Arthritis Therapeutics Market Concentration Ratio 3.2.1 Global Canine Arthritis Therapeutics Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Canine Arthritis Therapeutics Revenue in 2019 3.3 Canine Arthritis Therapeutics Key Players Head office and Area Served 3.4 Key Players Canine Arthritis Therapeutics Product Solution and Service 3.5 Date of Enter into Canine Arthritis Therapeutics Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Canine Arthritis Therapeutics Historic Market Size by Type (2015-2020) 4.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Type (2021-2026) 5 Canine Arthritis Therapeutics Breakdown Data by Application (2015-2026) 5.1 Global Canine Arthritis Therapeutics Market Size by Application (2015-2020) 5.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Canine Arthritis Therapeutics Market Size (2015-2020) 6.2 Canine Arthritis Therapeutics Key Players in North America (2019-2020) 6.3 North America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 6.4 North America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 7 Europe 7.1 Europe Canine Arthritis Therapeutics Market Size (2015-2020) 7.2 Canine Arthritis Therapeutics Key Players in Europe (2019-2020) 7.3 Europe Canine Arthritis Therapeutics Market Size by Type (2015-2020) 7.4 Europe Canine Arthritis Therapeutics Market Size by Application (2015-2020) 8 China 8.1 China Canine Arthritis Therapeutics Market Size (2015-2020) 8.2 Canine Arthritis Therapeutics Key Players in China (2019-2020) 8.3 China Canine Arthritis Therapeutics Market Size by Type (2015-2020) 8.4 China Canine Arthritis Therapeutics Market Size by Application (2015-2020) 9 Japan 9.1 Japan Canine Arthritis Therapeutics Market Size (2015-2020) 9.2 Canine Arthritis Therapeutics Key Players in Japan (2019-2020) 9.3 Japan Canine Arthritis Therapeutics Market Size by Type (2015-2020) 9.4 Japan Canine Arthritis Therapeutics Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Canine Arthritis Therapeutics Market Size (2015-2020) 10.2 Canine Arthritis Therapeutics Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Canine Arthritis Therapeutics Market Size by Type (2015-2020) 10.4 Southeast Asia Canine Arthritis Therapeutics Market Size by Application (2015-2020) 11 India 11.1 India Canine Arthritis Therapeutics Market Size (2015-2020) 11.2 Canine Arthritis Therapeutics Key Players in India (2019-2020) 11.3 India Canine Arthritis Therapeutics Market Size by Type (2015-2020) 11.4 India Canine Arthritis Therapeutics Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Canine Arthritis Therapeutics Market Size (2015-2020) 12.2 Canine Arthritis Therapeutics Key Players in Central & South America (2019-2020) 12.3 Central & South America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 12.4 Central & South America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Elanco (Eli Lilly and Company) 13.1.1 Elanco (Eli Lilly and Company) Company Details 13.1.2 Elanco (Eli Lilly and Company) Business Overview and Its Total Revenue 13.1.3 Elanco (Eli Lilly and Company) Canine Arthritis Therapeutics Introduction 13.1.4 Elanco (Eli Lilly and Company) Revenue in Canine Arthritis Therapeutics Business (2015-2020)) 13.1.5 Elanco (Eli Lilly and Company) Recent Development 13.2 Boehringer Ingelheim 13.2.1 Boehringer Ingelheim Company Details 13.2.2 Boehringer Ingelheim Business Overview and Its Total Revenue 13.2.3 Boehringer Ingelheim Canine Arthritis Therapeutics Introduction 13.2.4 Boehringer Ingelheim Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.2.5 Boehringer Ingelheim Recent Development 13.3 Zoetis Inc 13.3.1 Zoetis Inc Company Details 13.3.2 Zoetis Inc Business Overview and Its Total Revenue 13.3.3 Zoetis Inc Canine Arthritis Therapeutics Introduction 13.3.4 Zoetis Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.3.5 Zoetis Inc Recent Development 13.4 Vetoquinol S.A. 13.4.1 Vetoquinol S.A. Company Details 13.4.2 Vetoquinol S.A. Business Overview and Its Total Revenue 13.4.3 Vetoquinol S.A. Canine Arthritis Therapeutics Introduction 13.4.4 Vetoquinol S.A. Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.4.5 Vetoquinol S.A. Recent Development 13.5 Bayer AG 13.5.1 Bayer AG Company Details 13.5.2 Bayer AG Business Overview and Its Total Revenue 13.5.3 Bayer AG Canine Arthritis Therapeutics Introduction 13.5.4 Bayer AG Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.5.5 Bayer AG Recent Development 13.6 Aratana Therapeutics Inc 13.6.1 Aratana Therapeutics Inc Company Details 13.6.2 Aratana Therapeutics Inc Business Overview and Its Total Revenue 13.6.3 Aratana Therapeutics Inc Canine Arthritis Therapeutics Introduction 13.6.4 Aratana Therapeutics Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.6.5 Aratana Therapeutics Inc Recent Development 13.7 Norbrook Laboratories Limited 13.7.1 Norbrook Laboratories Limited Company Details 13.7.2 Norbrook Laboratories Limited Business Overview and Its Total Revenue 13.7.3 Norbrook Laboratories Limited Canine Arthritis Therapeutics Introduction 13.7.4 Norbrook Laboratories Limited Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.7.5 Norbrook Laboratories Limited Recent Development 13.8 VetStem Biopharma 13.8.1 VetStem Biopharma Company Details 13.8.2 VetStem Biopharma Business Overview and Its Total Revenue 13.8.3 VetStem Biopharma Canine Arthritis Therapeutics Introduction 13.8.4 VetStem Biopharma Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.8.5 VetStem Biopharma Recent Development 13.9 Dechra Pharmaceuticals Plc 13.9.1 Dechra Pharmaceuticals Plc Company Details 13.9.2 Dechra Pharmaceuticals Plc Business Overview and Its Total Revenue 13.9.3 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Introduction 13.9.4 Dechra Pharmaceuticals Plc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.9.5 Dechra Pharmaceuticals Plc Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 - Cole of Duty

BrainStorm Cell Therapeutics to Join the Russell 2000 Index and Russell 3000 Index – Yahoo Finance

By adminJune 26, 2020Adult Stem Cells

NEW YORK, June 23, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NasdaqCM: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000 Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit http://www.ftserussell.com/.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations: Michael Rice LifeSci Advisors, LLC Phone: +1 646 889 1200 mrice@lifesciadvisors.com

Public Relations: Paul Tyhala SmithSolve 973.442.1555 paul.tyahla@smithsolve.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-join-the-russell-2000-index-and-russell-3000-index-301081791.html

SOURCE Brainstorm Cell Therapeutics Inc

Excerpt from:
BrainStorm Cell Therapeutics to Join the Russell 2000 Index and Russell 3000 Index - Yahoo Finance

COVID-19 impact: Stem Cells Market to Witness Steady Expansion During 2019-2026 – Personal Injury Bureau UK

By adminJune 26, 2020Adult Stem Cells

The report on the Stem Cells market provides a birds eye view of the current proceeding within the Stem Cells market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Stem Cells market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Stem Cells market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The Stem Cells market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Stem Cells market and the trends that will prevail in this industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2649650&source=atm

What pointers are covered in the Stem Cells market research study?

The Stem Cells market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Stem Cells market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Stem Cells market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Regional and Country-level Analysis The report offers an exhaustive geographical analysis of the global Stem Cells market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026. Competition Analysis In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cells market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cells market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cells market. The following players are covered in this report: CCBC Vcanbio Boyalife Beikebiotech Stem Cells Breakdown Data by Type Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other Stem Cells Breakdown Data by Application Diseases Therapy Healthcare

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2649650&source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Stem Cells market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Stem Cells market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Stem Cells market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2649650&licType=S&source=atm

Some of the Major Highlights of TOC covers:

See the original post:
COVID-19 impact: Stem Cells Market to Witness Steady Expansion During 2019-2026 - Personal Injury Bureau UK

Aviva Woman Is Providing Facial Treatments and Erectile Dysfunction Therapy in Salt Lake City – Press Release – Digital Journal

By adminJune 26, 2020Platelet Rich Plasma Injections

This press release was orginally distributed by SBWire

Millcreek, UT -- (SBWIRE) -- 06/25/2020 -- Aviva Woman has established itself as a sanctuary-like clinic in Millcreek, Utah, where it provides women and couples with intimate health solutions. The medical spa takes pride in providing its clients with a welcoming environment where personalized care is the number one priority. To achieve this, Aviva Woman maintains a team of care providers who are well-trained and have been certified to provide therapies and treatments for various needs.

Talking about why they are the best team to address sensitive healthcare concerns, the company's spokesperson commented, "It is never easy for most men and women to talk about their intimate health concerns. Primarily this is because they lack the right atmosphere and discerning professionals for this. At Aviva Woman, you have access to a spa facility where you will instantly feel relaxed and have the needed privacy to discuss these issues. Our experts' personal understanding of these concerns makes it better as you get to have the confidence of being in safe hands. Most importantly, we will do all we can to help you feel like You again."

The secret to having beautiful skin is maintaining a daily ritual, whereby a lot of attention is paid on giving your body the care it deserves. These efforts are to be complemented by professional care that significantly boosts these daily activities. Aviva Woman is making it more straightforward for men and women to adhere to these personal care routines as it provides facial treatments in Utah. As such, men and women looking for professionals who provide chemical peel in Salt Lake City will find the facility suitable for their demands.

Speaking about how they assist men in tackling their erectile dysfunction problems, the company's spokesperson said, "Statistics show that there has been an increase in the percentage of men who have erectile dysfunction, especially those over the age of 50 years. This is not a pleasant statistic, but the good news is that no man need ever suffer in silence. We assist you to overcome this medical condition through our platelet-rich plasma penile injections, which is a modern regenerative treatment. It is a painless procedure that uses your own blood plasma to improve the functioning of the erectile tissue."

There are a variety of facial treatments provided by Aviva Woman for men and women looking for skilled estheticians offering the best facials Salt in Lake City. The spa focuses on providing customized facial treatments aligned to each client's skincare goals. Among the popular facial therapies that Aviva Woman offers are enzyme masks, anti-aging facelift facial, microdermabrasion, and vitamin C European facial. As a policy, before any of these treatments are provided, the specialists ask a series of questions and provide guidance on after-care procedures.

About Aviva Woman Aviva Woman specializes in assisting men, women, and couples in handling their intimate health concerns and taking care of their bodies by providing specialized procedures that include PRP treatment for erectile dysfunction.

For more information on this press release visit: http://www.sbwire.com/press-releases/aviva-woman-is-providing-facial-treatments-and-erectile-dysfunction-therapy-in-salt-lake-city-1294859.htm

Go here to read the rest:
Aviva Woman Is Providing Facial Treatments and Erectile Dysfunction Therapy in Salt Lake City - Press Release - Digital Journal

Tendinitis Treatment Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE – Cole of Duty

By adminJune 26, 2020Platelet Rich Plasma Injections

The Global Tendinitis Treatment Market is segmented on the lines of its technology, treatment, application and regional. Based on Type analysis it consists of Achilles tendinitis, supraspinatus tendinitis, tennis or golfers elbow, De Quervains tenosynovitis, and others. On the basis of treatment analysis includes diagnosis, therapy, shock wave therapy or surgery, medical devices, devices, and others. Diagnosis is again classified as physical examination, imaging tests, ultrasound, Magnetic Resonance Imaging (MRI) Scans, and others. Therapy is further segmented as non-pharmacological and pharmacological therapy. Non-pharmacological therapy includes rest therapy, heat & cold therapy, occupational therapy, physical therapy, and others. Pharmacological therapy includes OTC drugs or pain relievers, corticosteroids injections, platelet-rich plasma (PRP), and others. Medical devices segment is again segmented as mechanical band, support tape, pre-cut strips, continuous rolls, and others. On the basis of end user analysis it covers hospitals, clinics, medical research centers, academic institutes, and others. The Global Tendinitis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

You Can Browse Full Report: https://www.marketresearchengine.com/tendinitis-treatment-market

The Global Tendinitis Treatment Market is expected to be around US$ 8646.3 Million by 2025 at a CAGR of 7.2% in the given forecast period.

The scope of the report includes a detailed study of global and regional markets on Tendinitis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Tendinitis is the irritation of the ligament, thick strings that attache the muscles deep down. The aggravation happens because of sudden damage to the ligament, monotonous development or sickness condition, for example, diabetes, rheumatoid joint pain, gout, Reiters disorder or lupus. If there should be an occurrence of patients with gout, the uric corrosive precious stones show up in the ligament sheath prompting rubbing. Tendinitis is observed to be pervasive among competitors and is one of the normal game wounds in wear players, particularly tennis, golf and others. Different pharmacological and non-pharmacological medications are accessible for the treatment of tendinitis. Non-Steroidal Anti-incendiary Drugs (NSAIDs) constitute the preparatory treatment alternatives. Different medicines including active recuperation, rest, and word related treatment. Surgery is the final resort for tendinitis, and is just prescribed if there should be an occurrence of extreme harm to the ligament that cant be dealt with utilizing pharmacological treatment alternatives.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer (U.S.), AstraZeneca (U.K), Bayer (Germany), Abbott (U.S.), Merck & Co. Inc. (Germany), GlaxoSmithKline plc (U.S.), Boehringer Ingelheim Pharmaceuticals, Inc. (Germany), Teva Pharmaceutical Industries (Israel). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Global Tendinitis Treatment Market has been segmented as below:

The Global Tendinitis Treatment Market is Segmented on the lines of Type Analysis, Treatment Analysis, End User Analysis and Regional Analysis. By Type Analysis this market is segmented on the basis of Achilles tendinitis, Supraspinatus tendinitis, Tennis or golfers elbow, De Quervains tenosynovitis and Others. By Treatment Analysis this market is segmented on the basis of Diagnosis its covers Physical examination, Imaging tests, Ultrasound, Magnetic Resonance Imaging (MRI) Scans & Others. Therapy its covers Non-pharmacological therapy likes Rest therapy, Heat & cold therapy, Occupational therapy, Physical therapy & Others. Pharmacological therapy likes OTC drugs or pain relievers, Corticosteroids injections, Platelet-rich plasma (PRP) & Others. Shock wave therapy or surgery its covers Medical devices, Mechanical band, Support tape, Pre-cut strips & Others. Devices like Others.

By End User Analysis this market is segmented on the basis of Hospitals sector, Clinics sector, Medical research centers sector, Academic institutes sector and Others sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Tendinitis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Global Tendinitis Treatment Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Request Sample Report: https://www.marketresearchengine.com/tendinitis-treatment-market

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Tendinitis Treatment Market. 2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast of Global Tendinitis Treatment Market data. 4) Assess your competitors refining portfolio and its evolution.

The major driving factors of Global Tendinitis Treatment Market are as follows:

The restraining factors of Global Tendinitis Treatment Market are as follows:

Other Related Market Research Reports:

Tissue Regeneration Market is Expected to Grow US$ 60 Billion By 2022

Hyaluronic Acid Based Dermal Fillers Market is expected to exceed more than US$ 14.9 Billion by 2024

Sample Preparation Market Key Enhancement, Product Overview and Share Forecasted to 2024

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

See original here:
Tendinitis Treatment Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer…

By adminJune 26, 2020Stem Cell Clinic

Tom Farrell didnt have much to do after Bellicum announced in January 2017 that they were bringing in a new CEO. He had led the CAR-T company for over a decade, since before Carl Junes New England Journal of Medicinepaper had made cell therapy the hottest thing in cancer research. Now he was facing an 18-month non-compete.

So he worked quickly when, not long after that clock expired in 2018, a banker who helped take Bellicum public told him about a South Korean company called Green Cross LabCell that had built a natural killer cell factory and was looking to develop therapies off it. Farrell hopped a plane to Seoul.

It was hugely impressive, Farrell told Endpoints News.There was nothing [else] I came across that was truly disruptive from a business model perspective.

A year and a half later, Farrell has his new company. Called Artiva, it launches with $78 million in Series A funding and an exclusive deal with Green Cross to push some of their natural killer cell technology into the clinic. Theyll start with a therapy that combines NKs with an approved antibody therapy like rituximab to improve the antibodys effectiveness. Behind that, theyre working on CAR-NK therapy and, longer term, gene-edited CAR-NK cells. RA Capital Management, venBio and 5AM Ventures led the round.

Artiva joins what, after many years, has recently become a booming field. In February, MD Anderson showed that a Takeda-licensed CAR-NK therapy cleared tumors completely in 7 of 11 non-Hodgkins lymphoma patients. Two months later, J&J gave Fate Therapeutics, one of the earliest biotechs in the field, an up-to $3.1 billion deal for their CAR-NK and CAR-T therapies. The Big Pharmas are joined by a slate of recent upstarts, including Celularity, Nkarta, NantKwest, and Cytovia.

Unlike the other newcomers, Artiva makes virtually no claim on having original science. In fact, Farrell said, biotechs emphasis on novel technologies is part of why cell therapy has advanced only incrementally since the approval of the first two CAR-T therapies. Industry hasnt focused enough on addressing the manufacturing issues that have made therapies so costly and difficult to scale, he said.

Lewis Lanier, an immunologist at the University of California, San Francisco and an early pioneer in NK cell research, said Artiva would still face the same questions other drug developers face will some patient reject the cells? Will the natural killer cells actually last a significant amount of time after infusion? but the collaboration could give them an edge.

The Korean Green Cross manufacturing facility is really first rate, thats where the advantage is, Lanier, who is not involved in Artiva, told Endpoints. The science is really routine, theyre not doing anything particularly innovative.

For years, NK cells have been viewed as one of the key potential ways of making off-the-shelf cell therapy. Part of the innate immune system, implanting these cells from donors doesnt lead to the same resistance that donor T cells can. One of the problems, though, is that NKs are finicky, as Lanier puts it, vastly more difficult to grow and manipulate in a lab. Only recently have a couple companies figured out ways to do it consistently. Fate, for instance, uses master lines of iPSC stem cells.

At the Green Cross facility Farrell toured two Novembers ago, the South Korean company had refined a process to derive NK cells from donated umbilical cord blood and cryo-preserve it. A week after his tour, Farrell flew to San Diego for the ASH conference, where he ran into Pete Flynn, another longtime biotech executive out of a job. Flynn had run early development for Fate in its early years before leaving to run R&D for the anti-obesity company Orexigen, which had just gone bankrupt.

Farrell explained what he saw in Seoul and the two debated different approaches to off-the-shelf therapy. They figured the manufacturing base could be a launching pad.

Even though were a Series A company, were looking to become the go-to NK cell, Flynn, now COO, told Endpoints. Basically all the pieces are in place already, whereas for some of those other companies, there might still be some work to do.

Go here to see the original:
Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer...

Cernostics Announces Blinded, Independent Validation of TissueCypher(R) Performance for Predicting Risk of Progression to Esophageal Cancer in…

By adminJune 26, 2020Stem Cell Clinic

PITTSBURGH, June 25, 2020 /PRNewswire/ --Cernostics, a leader in the development of AI-driven image analysis technologies for precision medicine testing, today announced publication of new clinical results demonstrating further validation of how its TissueCypher(R) diagnostic test predicts future disease progression in patients with Barrett's Esophagus (BE). (Abstract available here. Full article available via journal subscription.) By identifying "at-risk" patients much earlier than traditional methods, TissueCypher provides actionable results that allow physicians to target early therapeutic interventions to prevent cancer.

TissueCypher is the first and only precision medicine test designed, developed, and commercialized to predict which patients with Barrett's Esophagus will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

In this study, funded by the NIH/NCI, patients with BE who progressed to HGD or EAC after at least one year following endoscopy (n=58) were matched to patients with BE without disease progression after a median of seven years surveillance (n=210). Results demonstrated that patients classified as high-risk by TissueCypher were at 4.7-fold increased risk for HGD/EAC compared to those classified as low-risk (p<0.0001). Furthermore, this study demonstrated that patients with non-dysplastic BE who TissueCypher scored high-risk progressed to HGD or EAC at a rate of more than 5%/year, which is at least a 10-fold increase in reported progression rates for NDBE, based on large population studies.

In an editorial accompanying the published results, Prasad G. Iyer, MD, MSc, at Mayo Clinic in Rochester, Minnesota, describes TissueCypher as the potential "Holy Grail" for Barrett's Esophagus. "Identification of those at higher risk may allow either intensive endoscopic surveillance (to detect incident dysplasia/EAC) or proactive EET, whereas surveillance intervals could be lengthened in those at low risk. This risk prediction has been referred to as the 'Holy Grail' in BE."

"This is the third independent study showing that TissueCypher gives physicians crucial predictive power beyond expert diagnosis, especially in that difficult subset of patients whose true risk may go unnoticed if we rely solely on traditional methods," said lead author Jon M. Davison, MD, Associate Professor of Pathology at University of Pittsburgh in Pittsburgh, Pennsylvania.

TissueCypher's unique advantages stem from its patented, AI-based digital platform with multi-channel fluorescence imaging that provides physicians with a more in-depth, accurate, and comprehensive view of each patient's unique pathology.

"The TissueCypher image analysis platform simultaneously and objectively extracts protein expression information from multiple biomarkers, as well as provides a digital expression of tissue architecture and nuclear morphology," says Vani J.A. Konda, MD, Clinical Director, Center for Esophageal Diseases, at Baylor University Medical Center in Dallas, Texas, and a key opinion leader in the use of imaging and novel screening techniques to improve early detection and treatment. "The information physicians receive is meaningful, accurate, and immediately actionable." Dr. Konda has published extensively on the role of biomarkers for improving risk stratification in patients with Barrett's Esophagus, including an upcoming review paper in the July 2020 issue of Gastroenterology & Endoscopy News.

Cernostics' innovative technology is unique in today's market because tissue structure is preserved while immune, stromal, stem cell and tumor biomarkers are analyzed all of which is done by evaluation of standard esophageal pinch biopsies readily available from the endoscopy procedure. Biomarker intensity and spatial relationships within the tissue structure are also analyzed and reported, creating an in-depth picture of the patient's risk from which the physician can create successful patient management protocols.

TissueCypher has been tested and validated in five independent clinical studies at leading centers around the world, including Cleveland Clinic, University of Pennsylvania Medical Center, Geisinger Health, and Academic Medical Center in Amsterdam. Most recent peer-reviewed results are published currently in the June 2020 issue of the American Journal of Gastroenterology.

Using a pinch biopsy specimen routinely collected by the gastroenterologist during an endoscopy procedure, TissueCypher is easily incorporated into a physician's current practice. The test requires no additional tools or collection devices, as are needed with other currently available diagnostic options.

About Barrett's Esophagus

Barrett's Esophagus (BE) affects more than three million Americans, occurring when chronic exposure to stomach acid causes the esophageal cell lining to deteriorate and undergo changes that can create an environment for cancer. Without treatment, Barrett's can lead to EC, with a poor five-year survival of less than 20%. Today, Barrett's is commonly managed by surveillance, involving regular endoscopic procedures with biopsy, monitoring disease progression, and GERD-related drug therapy to control symptoms and prevent esophageal injury.

About Cernostics

Cernostics, a leader in tissue-based diagnostic testing, provides diagnostic tests with deeper tissue insights, better patient outcomes, and lower cost of care. Cernostics' mission is to quantify the tissue system complexity, providing physicians and patients with individualized, actionable information to improve outcomes and reduce the incidence and mortality of cancer. For a complete listing of Cernostics' published patents, visitwww.cernostics.com/IP.

Media Contact:

Lisa Bichsel

Cernostics

Tel: +1 719-640-5640

Email: lbichsel@cernostics.com

Related Images

tissuecypher-sample-image.jpg TissueCypher Sample Image TissueCypher detected multiple high-risk features in this biopsy from a patient with short segment, non-dysplastic Barrett's esophagus, as confirmed by the GI subspecialist. TissueCypher scored this case High Risk for progression to HGD/EAC within five years. The patient was diagnosed with HGD on surveillance endoscopy 2.5 years later.